⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2644357 | 1.00 | — | — | |
| SCHEMBL4618860 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL19876854 | 0.98 | LMNA (0.45) | — | |
| Hydrochloric Acid SCHEMBL19876853 | 0.98 | LMNA (0.45) | — | |
| SCHEMBL14037307 | 0.87 | TSHR (0.40) | — | |
| SCHEMBL20677353 | 0.87 | TSHR (0.40) | — | |
| SCHEMBL574347 | 0.86 | FAAH (0.46) | — | |
| SCHEMBL6054606 | 0.86 | FAAH (0.46) | — | |
| SCHEMBL290509 | 0.86 | FAAH (0.46) | — | |
| SCHEMBL10952947 | 0.85 | MME (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4466069-A1 | GLP-1/GIP RECEPTOR CO-AGONIST PRODRUGS AND USES THEREOF | Novo Nordisk A/S (DK) | 2024-11-27 | — | — | EP | claimed |
| CN-118632867-A | GLP-1/GIP receptor co-agonist prodrugs and uses thereof | 诺和诺德股份有限公司 | 2024-09-10 | — | — | CN | claimed |
| US-20240083965-A1 | PRODRUGS AND USES THEREOF | NOVO NORDISK AS (DK) | 2024-03-14 | — | — | US | claimed |
| WO-2023139187-A1 | GLP-1/GIP RECEPTOR CO-AGONIST PRODRUGS AND USES THEREOF | NOVO NORDISK A/S (DK) | 2023-07-27 | — | — | WO | claimed |
| US-20230227521-A1 | PRODRUGS AND USES THEREOF | NOVO NORDISK A/S (DK) | 2023-07-20 | — | — | US | claimed |
| CN-111019987-A | Preparation method of glutamine dipeptide | 江苏诚信药业有限公司 | 2020-04-17 | — | — | CN | claimed |
| WO-2009051555-A2 | MODIFIED MHC CLASS I BINDING PEPTIDES | AKADEMISCH ZIEKENHUIS LEIDEN (NL) | 2009-04-23 | — | — | WO | claimed |
| EP-0950046-B1 | 3,4-DISUBSTITUTED AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE REGULATORS | NAEJA PHARMACEUTICAL INC (CA) | 2002-04-10 | — | — | EP | claimed |
| US-6232305-B1 | ANTICANCER AGENTS; BONE DISORDERS; ANTIARTHRITIC AGENTS; RESPIRATORY SYSTEM DISORDERS | NAEJA PHARMACEUTICAL INC. (CA) | 2001-05-15 | — | — | US | claimed |
| EP-4466069-A1 | GLP-1/GIP RECEPTOR CO-AGONIST PRODRUGS AND USES THEREOF | Novo Nordisk A/S (DK) | 2024-11-27 | — | — | EP | disclosed |
| CN-118632867-A | GLP-1/GIP receptor co-agonist prodrugs and uses thereof | 诺和诺德股份有限公司 | 2024-09-10 | — | — | CN | disclosed |
| US-20240083965-A1 | PRODRUGS AND USES THEREOF | NOVO NORDISK AS (DK) | 2024-03-14 | — | — | US | disclosed |
| WO-2024043249-A1 | CYCLIC PEPTIDE OR SALT THEREOF AND MDMX INHIBITOR | 富士フイルム株式会社 | 2024-02-29 | — | — | WO | disclosed |
| WO-2024043250-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | 富士フイルム株式会社 | 2024-02-29 | — | — | WO | disclosed |
| EP-0384522-B1 | Antiviral tetrahydroimidazo[1,4]benzodiazepin-2-thiones | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-01-13 | — | — | EP | disclosed |
| WO-1991004246-A1 | METHOD FOR PREPARING AMINO ACID DERIVATIVES AND THERAPEUTICAL APPLICATIONS OF SAME | SOCIETE CIVILE BIOPROJET (FR) | 1991-04-04 | — | — | WO | disclosed |
| EP-0384522-A1 | Antiviral tetrahydroimidazo[1,4]benzodiazepin-2-thiones | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-08-29 | — | — | EP | disclosed |
| US-4421641-A | REVERSE FLOTATION | CECA S.A. (FR) | 1983-12-20 | — | — | US | disclosed |
| US-4413005-A | 2,3-DIHYDRO-2,2-DIMETHYLBENZOFURAN-7-YL DERIVATIVES | OTSUKA KAGAKU YAKUHIN KABUSHIKI KAISHA (JP) | 1983-11-01 | — | — | US | disclosed |
| US-4143159-A | SKIN-CARE AGENTS CONTAINING HYDROXYALKYL CARBOXAMIDES AND PROCESS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1979-03-06 | — | — | US | disclosed |